



Un-Audited Financial Statements For the Nine months
and Three months ended September 30, 2025



Corporate Information

BOARD OF DIRECTORS

Ehsan Ali Malik (Chairman) (Non-Executive Director)

Syed Anis Ahmed (Chief Executive Officer)

Celestino Jacinto Dos Anjos (Non-Executive Director)

Ayla Majid (Independent Director)

Mohsin Ali Nathani (Independent Director)

Seema Khan (Executive Director)

AUDIT COMMITTEE

Mohsin Ali Nathani (Chairman)

Ayla Majid

Celestino Jacinto Dos Anjos

HUMAN RESOURCE AND REMUNERATION COMMITTEE

Mohsin Ali Nathani (Chairman)

Ehsan Ali Malik

Syed Anis Ahmed

RISK MANAGEMENT COMMITTEE

Ayla Majid (Chairperson)

Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

SHARE TRANSFER COMMITTEE

Syed Anis Ahmed (Chairman)

Celestino Jacinto Dos Anjos

Seema Khan

BANKING COMMITTEE

Mohsin Ali Nathani (Chairman)

Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

NOMINATION COMMITTEE

Ehsan Ali Malik (Chairman)

Mohsin Ali Nathani

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Tabish Aseem

COMPANY SECRETARY

Muhammad Usama Jamil

CHIEF INTERNAL AUDITOR

Muhammad Ali Shiwani

AUDITORS

EY Ford Rhodes, Chartered Accountants
(a member firm of Ernst & Young Global Limited)

LEGAL ADVISORS

Orr, Dignam & Co.

Surridge & Beecham

BANKERS

Standard Chartered Bank (Pakistan) Limited

Deutsche Bank AG

Habib Bank Limited

National Bank of Pakistan

MCB Bank Limited

Faysal Bank Limited

Habib Metropolitan Bank

Citibank

SENIOR MANAGEMENT TEAM

Syed Anis Ahmed

(Chief Executive Officer)

Syed Tabish Aseem

(Chief Financial Officer)

Moien Ahmed Khan

(Director Operations)

Asim Shafiq

(General Manager, Abbott Nutrition

International Pakistan)

Saad Siddique

(Country Manager, Abbott Diagnostics

Division Pakistan)

Dr. Shaikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Asghar Huda

(Director Human Resource)

SHARE REGISTRAR

FAMCO Share Registration Services (Pvt)

Limited, 8-F, Next to Hotel Faran, Nursery

Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi.

FACTORY LOCATIONS

Plot No. 258 & 324, Opposite Radio

Pakistan Transmission Centre,

Hyderabad Road, Landhi, Karachi.

Plot No. 13, Sector 20,

Korangi Industrial Area, Karachi.

CITY OFFICE

11th & 12th Floors

Ocean Tower, G-3, Block 9

Main Clifton Road, Karachi 75600.

P.O. Box 13841

Tel: +92-21-111-Abbott (111-222-688)

SALES OFFICES

House No. 25/III/B, Jamrud Lane,

University Town, Peshawar, Pakistan.

House No. 187, Aurangzeb Block,

Near Garden Town, Lahore, Pakistan.

WAREHOUSES

Plot No. 136, Street # 9, Sector I-10/3,

Industrial Area, Islamabad.

16 KM Shahpur Kanjran,

Multan Road, Lahore.

Hasanabad Gate # 2,

Near Pak Arab Fertilizers,

Khanewal Road, Multan..

WEBSITE

www.pk.abbott

Directors' Report

The Directors are pleased to present the un-audited condensed interim financial statements of your Company, for the nine months ended September 30, 2025, as well as for the third quarter ended September 30, 2025.

FINANCIAL HIGHLIGHTS

For nine months' period ended September 30, 2025

Overall sales increased by 13% over the same period last year. Pharmaceutical sales increased by 16% driven by sustained performance of established brands. Nutritional sales increased by 19% mainly driven by price adjustments, while Diagnostics segment were down by 16% vs. same period last year mainly due to a one-off tender business impact in 2024 sales.

Gross profit margin of your Company during this period improved to 34% vs 28% during the same period last year, mainly driven by price adjustments and various other efficiency measures taken across the Company. Gross margin for the pharmaceutical segment improved to 33% from 29%, whereas the gross margin for Nutritional segment increased to 44% from 35% vs same period last year.

Selling and distribution expenses increased by 19% against the same period last year mainly due to increased marketing and advertisement activities; part of selling and distribution expense is augmented by prior years' inflation adjustments. Net profit as a percentage of sales improved to 10% versus 8% during same period last year.

For third quarter ended September 30, 2025

Sales for the quarter increased by 14% over the same period last year. Pharmaceutical as well as nutrition sales increased by 16%.

Similar to the year-to-date results, gross profit margin of the Company improved to 34% from 33% during the same period last year on account of reasons mentioned above.

Operating expenses increased by 22% over the same period last year on account of higher sales promotion and forwarding expenses. Other charges increased by PKR 180 million over the same period last year due to increase in statutory charges in line with improved profitability.

FUTURE OUTLOOK

The pharmaceutical and healthcare landscape continues to show signs of resilience amid a gradually stabilizing macroeconomic environment. The Company's year-to-date performance, marked by double-digit growth in core segments and improved profitability, reflects the effectiveness of strategic actions and marketing initiatives.

Looking ahead, the sector's trajectory will depend on sustained regulatory reforms, particularly in pricing mechanisms for essential medicines, and continued fiscal discipline. While inflationary pressures and statutory cost escalations remain key challenges, your Company is well-positioned to navigate these through disciplined cost management and portfolio optimization.

With a focus on innovation, patient-centric solutions, and operational agility, your Company remains committed to deliver sustainable value to its stakeholders.



Syed Anis Ahmed
Chief Executive



Ehsan Ali Malik
Director

Karachi: October 29th 2025

ڈائریکٹرز رپورٹ

ڈائریکٹرز آپ کی کمپنی کے 30 ستمبر 2025 کو ختم ہونے والی نو مای کے ساتھ ساتھ 30 ستمبر 2025 کو ختم ہونے والی تیسری سہ مای کے لیے غیر آڈٹ شدہ عبوری مالی گوشوارے پیش کرتے ہوئے خوش محسوس کرتے ہیں۔

مالی جھلکیاں

30 ستمبر 2025 کو ختم ہونے والی نو مای کیلئے

گزشتہ سال کی اسی مدت کے مقابلے میں سبز میں 13 فیصد اضافہ ہوا۔ فارماسیوٹیکل سبز میں 16 فیصد اضافہ ہوا جس کی وجہ سے قائم برانڈز کی مسلسل کارکردگی ہے نیوٹریشنز کی فروخت میں 19 فیصد اضافہ ہوا جو بنیادی طور پر قیمتوں میں ایڈجسٹمنٹ کی وجہ سے ہے جبکہ ڈاگمناٹکس سیکٹ میں گزشتہ سال کے اسی عرصے کے مقابلے میں 16 فیصد کمی واقع ہوئی، جس کی بنیادی وجہ 2024 میں یکطرفہ مینڈر برنس کا اثر تھا۔

اس مدت کے دوران آپ کی کمپنی کے مجموعی منافع کا مارجن پچھلے سال کی اسی مدت کے مقابلے میں 28 فیصد سے بڑھ کر 34 فیصد ہو گیا، جو بنیادی طور پر قیمتوں میں ایڈجسٹمنٹ اور پوری کمپنی میں اٹھائے گئے مختلف دیگر کارکردگی کے اقدامات کی وجہ سے ہے۔ فارماسیوٹیکل طبقہ کے لیے مجموعی مارجن 29 فیصد سے بڑھ کر 33 فیصد ہو گیا، جبکہ نیوٹریشنز کے طبقے کے لیے مجموعی مارجن پچھلے سال کی اسی مدت کے مقابلے میں 35 فیصد سے بڑھ کر 44 فیصد ہو گیا۔

فروخت اور تقسیم کے اخراجات میں گزشتہ سال کے اسی عرصے کے مقابلے میں 19 فیصد اضافہ ہوا، جس کی بنیادی وجہ مارکیٹنگ اور اشتہاری سرگرمیوں میں اضافہ ہے؛ فروخت اور تقسیم کے اخراجات کا ایک حصہ گزشتہ سالوں کی مہنگائی کی ایڈجسٹمنٹ سے بڑھا ہے۔ خالص منافع، سبز کے تناسب سے، بہتر ہو کر 10 فیصد ہو گیا جبکہ گزشتہ سال اسی عرصے میں یہ 8 فیصد تھا۔

30 ستمبر 2025 کو ختم ہونے والی تیسری سہ مای کیلئے

گزشتہ سال کی اسی مدت کے مقابلے میں سہ مای کے لیے سبز میں 14 فیصد اضافہ ہوا۔ فارماسیوٹیکل کے ساتھ ساتھ نیوٹریشنز کی فروخت میں 16 فیصد اضافہ ہوا۔

سال کے اب تک کے نتائج کی طرح مذکورہ وجوہات کی بناء پر کمپنی کے مجموعی منافع کا مارجن گزشتہ سال کی اسی مدت میں 33 فیصد سے بڑھ کر 34 فیصد ہو گیا۔

آپریٹنگ اخراجات میں گزشتہ سال کے اسی عرصے کے مقابلے میں 22 فیصد اضافہ ہوا، جس کی بنیادی وجہ سبز پروموشن اور فارورڈنگ اخراجات میں اضافہ ہے۔

دیگر چارجز میں 180 ملین روپے کا اضافہ ہوا، جو کہ بہتر منافع کی وجہ سے قانونی چارجز میں اضافے کے باعث ہے۔

مستقبل کا مقررنامہ

فارماسیوٹیکل اور صحت کے شعبے میں موجودہ معاشی حالات کے بتدریج استحکام کے دوران مضبوطی کے آثار نمایاں ہیں۔ کمپنی کی سال بہ سال کارکردگی، جو بنیادی شعبوں میں دو ہندسی ترقی اور منافع میں بہتری سے مزین ہے، اس بات کی عکاسی کرتی ہے کہ اس کی حکمت عملی اور مارکیٹنگ اقدامات مؤثر ثابت ہوئے ہیں۔

آئندہ کے لیے، اس شعبے کی سمت کا انحصار مستقل ریگولیٹری اصلاحات پر ہوگا، خاص طور پر ضروری ادویات کی قیمتوں کے تعین کے نظام اور مالی نظم و ضبط کے تسلسل پر۔ اگرچہ مہنگائی کے دباؤ اور قانونی اخراجات میں اضافہ اہم چیلنجز ہیں، آپ کی کمپنی ان مسائل سے نمٹنے کے لیے مؤثر آلات کے نظم و نسق اور پورٹ فولیو کی بہتری کے ذریعے اچھی پوزیشن میں ہے۔

جدت طرازی، مریض پر مرکوز حل، اور آپریشنل چستی پر توجہ کے ساتھ، آپ کی کمپنی اپنے اسٹیک ہولڈرز کو پائیدار قدر فراہم کرنے کے لیے پرعزم ہے۔

ڈائریکٹر

چیف ایگزیکٹو

کراچی: 29 اکتوبر 2025ء

Condensed Interim Statement of Financial Position

As at September 30, 2025

	Note	September 30, 2025 (Un-audited)	December 31, 2024 (Audited)
Rupees in '000 -----			
ASSETS			
NON-CURRENT ASSETS			
Property, plant and equipment	6	14,702,339	14,252,797
Intangible assets		884	1,250
Long-term loans and advances		129,237	114,226
Long-term deposits		32,713	7,513
Long-term prepayments		10,078	13,710
		<u>14,875,251</u>	<u>14,389,496</u>
CURRENT ASSETS			
Stores and spares		570,438	529,619
Stock-in-trade	7	13,517,073	10,694,515
Trade debts		3,390,553	2,982,679
Loans and advances	8	1,047,173	938,021
Trade deposits and short-term prepayments	9	555,581	283,813
Other receivables	10	1,330,418	1,182,530
Taxation - net		240,470	468,136
Cash and cash equivalents	11	9,009,546	6,182,349
		<u>29,661,252</u>	<u>23,261,662</u>
TOTAL ASSETS		<u>44,536,503</u>	<u>37,651,158</u>
EQUITY AND LIABILITIES			
SHARE CAPITAL AND RESERVES			
Authorised capital			
200,000,000 ordinary shares of Rs.10 each		<u>2,000,000</u>	<u>2,000,000</u>
Issued, subscribed and paid-up capital	12	979,003	979,003
Reserves			
- Capital		1,993,957	1,750,481
- Revenue		25,381,867	20,995,152
		<u>27,375,824</u>	<u>22,745,633</u>
		<u>28,354,827</u>	<u>23,724,636</u>
NON-CURRENT LIABILITIES			
Deferred taxation - net		869,361	1,052,587
Staff retirement benefits		1,230,791	1,184,179
Lease liabilities		349,206	29,545
		<u>2,449,358</u>	<u>2,266,311</u>
CURRENT LIABILITIES			
Trade and other payables	13	12,681,033	10,951,662
Unclaimed dividends		71,605	63,715
Unpaid dividends		209,714	-
Current maturity of lease liabilities		85,873	22,683
Provisions		684,093	622,151
		<u>13,732,318</u>	<u>11,660,211</u>
CONTINGENCIES AND COMMITMENTS	14	<u>44,536,503</u>	<u>37,651,158</u>
TOTAL EQUITY AND LIABILITIES		<u>44,536,503</u>	<u>37,651,158</u>

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Condensed Interim Statement of Profit or Loss (Un-Audited)

For the nine months and three months ended September 30, 2025

	Nine Months Ended		Three Months Ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
Note	----- Rupees in '000 -----			
SALES - NET				
Local	53,909,372	47,273,134	18,995,527	16,784,001
Export	2,317,551	2,290,945	823,607	580,545
	56,226,923	49,564,079	19,819,134	17,364,546
Cost of sales	(36,886,086)	(35,493,642)	(13,093,197)	(11,634,162)
GROSS PROFIT	19,340,837	14,070,437	6,725,937	5,730,384
Selling and distribution expenses	(8,501,410)	(7,120,361)	(2,974,143)	(2,404,851)
Administrative expenses	(972,482)	(857,385)	(334,287)	(300,482)
Other charges	(1,256,699)	(578,954)	(430,365)	(250,259)
Other income	603,335	541,111	186,590	83,003
	(10,127,256)	(8,015,589)	(3,552,205)	(2,872,589)
	9,213,581	6,054,848	3,173,732	2,857,795
Finance costs	(55,363)	(18,587)	(17,659)	(5,988)
PROFIT BEFORE TAXATION	9,158,218	6,036,261	3,156,073	2,851,807
Minimum tax differential	(146,989)	(87,306)	(146,989)	79,576
	9,011,229	5,948,955	3,009,084	2,931,383
INCOME TAX				
Current	(3,828,736)	(1,913,620)	(1,181,163)	(1,182,528)
- For the year	-	32,253	-	32,253
- Prior year	183,225	(118,305)	(5,375)	28,035
Deferred	(3,645,511)	(1,999,672)	(1,186,538)	(1,122,240)
NET PROFIT FOR THE PERIOD	5,365,718	3,949,283	1,822,546	1,809,143
BASIC AND DILUTED EARNINGS PER SHARE (Rs. per share)				
	54.81	40.34	18.62	18.48

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Condensed Interim Statement of Comprehensive
Income (Un-Audited)

For the nine months and three months ended September 30, 2025

	Nine Months Ended		Three Months Ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
	----- Rupees in '000 -----			
Profit for the period	5,365,718	3,949,283	1,822,546	1,809,143
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	5,365,718	3,949,283	1,822,546	1,809,143

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.



Chief Executive Officer



Director



Chief Financial Officer

Condensed Interim Statement of Cash Flows (Un-Audited)

For the nine months ended September 30, 2025

	September 30, 2025	September 30, 2024
Note	----- Rupees in '000 -----	

CASH FLOWS FROM OPERATING ACTIVITIES

Cash generated from operations	17	9,020,548	4,136,473
Income tax paid		(3,748,060)	(2,411,024)
Long-term loans and advances - net		(15,011)	(12,953)
Long-term deposits - net		(25,200)	-
Long-term prepayments - net		3,632	(10,416)
Contributions to staff retirement benefit funds		(253,147)	(218,923)
Net movement in provisions		61,942	-
Net cash inflow from operating activities		5,044,704	1,483,157

CASH FLOWS FROM INVESTING ACTIVITIES

Additions to operating fixed assets and CWIP	6.1	(1,893,111)	(1,925,266)
Sale proceeds from disposal of property, plant and equipment		177,968	85,500
Interest income		345,737	329,970
Net cash outflow from investing activities		(1,369,406)	(1,509,796)

CASH FLOWS FROM FINANCING ACTIVITIES

Finance costs paid		(7,571)	(8,811)
Lease rentals paid		(79,131)	(117,729)
Dividends paid		(761,399)	(1,030,325)
Net cash outflow from financing activities		(848,101)	(1,156,865)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		2,827,197	(1,183,504)

CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD		6,182,349	5,036,712
---	--	------------------	------------------

CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	17.2	9,009,546	3,853,208
---	------	------------------	------------------

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Condensed Interim Statement of Changes in Equity (Un-Audited)

For the nine months ended September 30, 2025

Share Capital	Reserves					Total Equity
	Capital Reserves		Revenue Reserves		Total	
	Reserve Arising on Merger	Other	General Reserve	Un-appropriated Profit		

----- Rupees in '000 -----

Balance as at January 1, 2024 (Audited) 979,003 46,097 1,391,065 5,338,422 10,482,759 17,258,343 18,237,346

Transactions with owners, recorded directly in equity

Employee benefit cost under IFRS 2- 'Share based payments' - - 244,953 - - 244,953 244,953

**Total comprehensive income for the period ended
September 30, 2024**

Net profit for the period	-	-	-	-	3,949,283	3,949,283	3,949,283
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	3,949,283	3,949,283	3,949,283

Balance as at September 30, 2024 (Un-audited) 979,003 46,097 1,636,018 5,338,422 14,432,042 21,452,579 22,431,582

Balance as at January 01, 2025 (Audited) 979,003 46,097 1,704,384 5,338,422 15,656,730 22,745,633 23,724,636

Final dividend for the year ended December 31, 2024
@ Rs. 10/- per share

- - - - (979,003) (979,003) (979,003)

Employee benefit cost under IFRS 2- 'Share based payments'

- - 243,476 - - 243,476 243,476

**Total comprehensive income for the period ended
September 30, 2025**

Net profit for the period	-	-	-	-	5,365,718	5,365,718	5,365,718
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	5,365,718	5,365,718	5,365,718

Balance as at September 30, 2025 (Un-audited) 979,003 46,097 1,947,860 5,338,422 20,043,445 27,375,824 28,354,827

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Chief Executive Officer

Director

Chief Financial Officer

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2025

1. THE COMPANY AND ITS OPERATIONS

Abbott Laboratories (Pakistan) Limited (the Company) is a public limited Company incorporated in Pakistan on July 02, 1948, and its shares are quoted on Pakistan Stock Exchange. The address of its registered office is Plot No. 258 & 324, opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.

2. STATEMENT OF COMPLIANCE

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 - 'Interim Financial Reporting', issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.

3. BASIS OF PREPARATION

These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting and notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. These condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2024.

These condensed interim financial statements are presented in Pakistan Rupees, which is the Company's functional and presentation currency.

4. NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS

There are certain amendments to existing accounting and reporting standards that have become applicable to the Company for accounting periods beginning on or after January 01, 2025. These are either considered to not be relevant or do not have any significant impact and accordingly, have not been detailed in these condensed interim financial statements.

5. SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND FINANCIAL RISK MANAGEMENT

The preparation of condensed interim financial statements in conformity with approved accounting standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.

Judgements and estimates made by the management in the preparation of these condensed interim financial statements are the same as those applied in the Company's annual financial statements for the year ended December 31, 2024.

The Company's financial risk management objectives and policies are consistent with those disclosed in the annual financial statements as at and for the year ended December 31, 2024.

		September 30, 2025 (Un-audited)	December 31, 2024 ---- Rupees in '000 ---- (Audited)
	Note		
6. PROPERTY, PLANT AND EQUIPMENT			
Operating fixed assets	6.1 & 6.2	12,806,815	11,329,199
Capital work-in-progress	6.1	1,511,223	2,858,741
Right-of-use assets	6.3	384,301	64,857
		<u>14,702,339</u>	<u>14,252,797</u>

- 6.1** Following were the additions and disposals of operating fixed assets and capital work-in-progress during the period:

	Additions	Disposals	
	Cost	Cost	Accumulated Depreciation
	-----	Rupees in '000	-----
Plant and machinery	2,669,178	6,059	4,949
Vehicles	368,286	124,209	73,064
Office equipment	-	287	272
Computers	148,040	-	-
Service equipment	55,125	64,775	38,865
Capital work-in-progress - net of transfers	(1,347,518)	-	-
	<u>1,893,111</u>	<u>195,330</u>	<u>117,150</u>

- 6.2** Depreciation charge for the period ended September 30, 2025 amounting to Rs. 1,684.833 million (September 30, 2024: Rs. 1,254.010 million).

6.3 Right-of-use assets

		September 30, 2025 (Un-audited)	December 31, 2024 ---- Rupees in '000 ---- (Audited)
	Note		
Warehouses, sales offices and city office	6.3.1	<u>384,301</u>	<u>64,857</u>

- 6.3.1** Depreciation charge for the period ended September 30, 2025 amounted to Rs. 94.746 million (September 30, 2024: Rs. 63.165 million).

7. STOCK-IN-TRADE

		September 30, 2025 (Un-audited)	December 31, 2024 ---- Rupees in '000 ---- (Audited)
	Note		
Raw and packing materials [including stock-in-transit of Rs. 1,613.065 million (December 31, 2024: Rs. 1,312.217 million)]		6,264,558	6,026,056
Work-in-process		801,631	611,605
Finished goods [including stock-in-transit of Rs. 1,062.346 million (December 31, 2024: Rs. 426.328 million)]	7.1	6,973,843	4,439,354
		<u>14,040,032</u>	<u>11,077,015</u>
Less: provision for slow moving and obsolete items		<u>(522,959)</u>	<u>(382,500)</u>
		<u>13,517,073</u>	<u>10,694,515</u>

- 7.1** Stock-in-trade includes items costing Rs. 1,018.365 million (December 31, 2024: Rs. 875.646 million) valued at net realisable value of Rs. 753.033 million (December 31, 2024: Rs. 739.761 million) resulting in a write down of Rs. 265.332 million (December 31, 2024: Rs. 135.885 million)

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2025

8. LOANS AND ADVANCES

Represent loans and advances amounted to Rs. 60.530 million and Rs. 986.643 million (December 31, 2024: Rs. 52.451 million and Rs. 885.570 million), respectively, net of allowance.

9. TRADE DEPOSITS AND SHORT-TERM PREPAYMENTS

Represent trade deposits and short-term prepayments amounted to Rs. 361.014 million and Rs. 194.567 million (December 31, 2024: Rs. 190.395 million and Rs. 93.418 million), respectively, net of allowance.

10. OTHER RECEIVABLES

Includes sales tax receivable and due from related parties amounting to Rs. 657.165 million and Rs. 194.364 million (December 31, 2024: Rs. 656.551 million and Rs. 303.825 million), respectively.

	September 30, 2025	December 31, 2024
Note	---- Rupees in '000 ---- (Un-audited)	(Audited)

11. CASH AND BANK BALANCES

With banks

Saving accounts:

- local currency	11.1	7,278,437	4,610,252
------------------	------	-----------	-----------

Current accounts:

- local currency	93,647	17,532
- foreign currency	1,631,797	1,548,539
	1,725,444	1,566,071

In hand

- local currency	1,138	4,531
- foreign currency	4,527	1,495
	5,665	6,026

9,009,546	6,182,349
-----------	-----------

- 11.1 These saving accounts carry mark-up at the rate of 5% to 10.50% (December 31, 2024: 6.50% to 13.50%) per annum.

12. ISSUED, SUBSCRIBED AND PAID-UP CAPITAL

As at September 30, 2024, Abbott Asia Investments Limited, UK (the Holding Company) held 76,259,454 (December 31, 2024: 76,259,454) shares. The ultimate holding company is Abbott Laboratories, USA.

13. TRADE AND OTHER PAYABLES

Includes accrued liabilities amounted to Rs. 6,926.847 million (December 31, 2024: Rs. 5,344.592 million), bills payable of Rs. 3,065.791 million (December 31, 2024: Rs. 2,704.992 million).

14. CONTINGENCIES AND COMMITMENTS

- 14.1** The Company is defending various minor suits filed against it in various courts in Pakistan related to its business operations as at reporting date, which are not material to disclose as contingencies. The Company's management is confident, based on the advice of its legal advisors, that these suits will be decided in the Company's favour.

14.2 Commitments

- 14.2.1** Commitments for capital expenditure as at September 30, 2025, aggregated to Rs. 739.952 million (December 31, 2024: Rs. 802.658 million).
- 14.2.2** Commitments in respect of letters of credit as at September 30, 2025 aggregated to Rs.1,666.646 million (December 31, 2024: Rs. 1,603.211 million).
- 14.2.3** The Company has given bank guarantees as at September 30, 2024 of Rs. 991.002 million (December 31, 2024: 827.108 million) to the Customs Department, a utility company and other institutions against tenders.
- 14.2.4** The Company has obtained short-term financing facilities from various commercial banks amounting to Rs. 7,600 million (December 31, 2024: Rs. 6,600 million). These facilities can be utilised for letters of credit, guarantees and running finance / short-term loans. However, the running finance / short-term loan utilisation cannot exceed Rs. 3,290 million (December 31, 2024: Rs. 3,290 million). The running finance / short-term loan carries mark-up at rates ranging from KIBOR minus 0.25% to flat KIBOR (December 31, 2024: KIBOR minus 0.25% to flat KIBOR) per annum and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not utilised any amount against running finance / short-term loan facilities neither pledged its inventory at the statement of financial position date.

15. OTHER CHARGES

	Nine months ended September 30, 2025 (Un-audited)	Nine months ended September 30, 2024 (Un-audited)
	---- Rupees in '000 ----	
Exchange loss - net	164,174	-
Workers' Profit Participation Fund	492,570	329,492
Workers' Welfare Fund	200,618	113,754
Central Research Fund	92,507	62,278
Donations	17,500	15,242
Auditors' remuneration	11,019	7,936
Provision for expected credit loss on trade debts	277,941	50,101
Provision for expected credit loss on other receivables	370	151
	<u>1,256,699</u>	<u>578,954</u>

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the nine months ended September 30, 2025

	Nine months ended September 30, 2025 (Un-audited)	Nine months ended September 30, 2024 (Un-audited)
Note	----	----
	Rupees in '000	

16. OTHER INCOME

Income from financial assets

- term deposit receipts	-	73,746
- saving accounts	345,737	253,466
	345,737	327,212

Income from non-financial assets

Gain on disposal of property, plant and equipment - net	99,788	28,310
Exchange gain - net	-	16,209
Scrap sales	49,435	50,327
Others	108,375	119,053
	257,598	213,899
	<u>603,335</u>	<u>541,111</u>

17. CASH GENERATED FROM OPERATIONS

Profit before taxation	9,158,218	6,036,261
------------------------	-----------	-----------

Adjustment for non-cash changes and other items:

Depreciation of operating fixed assets	1,684,833	1,254,010
Depreciation of right-of-use assets	94,746	63,165
Amortisation of intangible assets	366	10,160
Provision / (reversal) for slow moving and obsolete stock in trade	140,459	(57,589)
Provision allowance for expected credit losses on trade debts	277,941	50,101
Allowance for expected credit losses on other receivables	370	151
Gain on disposal of property, plant and equipment	(99,788)	(28,310)
Interest income	(345,737)	(327,212)
Expense recognized in profit or loss in respect of equity-settled shared-based compensation	243,476	244,953
Staff retirement benefits	299,759	269,907
Finance costs	55,363	18,587
Working capital changes	17.1 (2,489,458)	(3,397,711)
	<u>9,020,548</u>	<u>4,136,473</u>

		Nine months ended September 30, 2025 (Un-audited)	Nine months ended September 30, 2024 (Un-audited)
		---- Rupees in '000 ----	
17.1 Working capital changes			
(Increase) / decrease in current assets			
Stores and spares		(40,819)	9,772
Stock-in-trade		(2,963,017)	210,321
Trade debts		(685,815)	(822,382)
Loans and advances		(109,152)	(868,194)
Trade deposits and short-term prepayments		(271,768)	48,357
Other receivables		(148,258)	624,713
		(4,218,829)	(797,413)
Increase in current liabilities			
Trade and other payables		1,729,371	(2,600,298)
		(2,489,458)	(3,397,711)
17.2 Cash and cash equivalents			
Cash and bank balances	11	9,009,546	3,358,208
Term deposit receipts		-	495,000
		9,009,546	3,853,208

18. TRANSACTIONS WITH RELATED PARTIES

The related parties of the Company comprise the holding company, ultimate holding company, group companies, employee retirement benefit plans, directors and key management personnel. All the transactions with related parties are entered into at agreed terms in the normal course of business as approved by the Board of Directors of the Company. Transactions with related parties during the period are as follows:

		Nine months ended September 30, 2025 (Un-audited)	Nine months ended September 30, 2024 (Un-audited)
		---- Rupees in '000 ----	
Holding Company			
Dividend paid		476,622	-
Group companies			
Sale of goods		766,910	927,745
Purchase of stock in trade		13,845,139	11,356,464
Technical service fee		271,924	229,761
Reimbursement of expenses - net		510,398	569,096
Other income		108,375	119,053
Retirement fund:			
Contribution to Pension fund		200,597	183,631
Contribution to Provident fund		134,449	117,547
Contribution to Gratuity fund		54,348	39,166
Key management personnel:			
Remuneration and other short-term employee benefits		618,006	597,052
Post-employment benefits		49,175	44,440

Notes to the Condensed Interim Financial Statements (Un-Audited)

For the three Months Ended March 31, 2025

19. SEGMENT ANALYSIS

19.1 Segment wise operating results for nine months ended (Un-audited):

	September 30, 2025					September 30, 2024				
	Pharmaceutical	Nutritional	Diagnostic	Others	Total	Pharmaceutical	Nutritional	Diagnostic	Others	Total
Rupees in '000										
Sales	42,163,391	15,341,992	4,747,227	1,616,640	63,869,250	36,216,485	12,880,060	4,782,679	1,553,683	55,432,907
Less:										
Sales return	62,028	53,083	322,733	9,912	447,756	72,759	35,735	-	3,435	111,929
Trade discounts	2,780,360	833,012	-	52,890	3,666,262	2,371,011	696,848	-	41,684	3,109,543
Sales tax and excise duty	372,497	2,411,874	590,011	153,927	3,528,309	303,454	2,019,003	236,498	88,401	2,647,356
Sales - net	38,948,506	12,044,023	3,834,483	1,399,911	56,226,923	33,469,261	10,128,474	4,546,181	1,420,163	49,564,079
Cost of sales	(26,013,849)	(6,747,956)	(3,220,290)	(903,991)	(36,886,086)	(23,865,039)	(6,584,778)	(3,921,477)	(1,102,348)	(35,493,642)
Gross profit	12,934,657	5,296,067	614,193	495,920	19,340,837	9,584,222	3,543,696	624,704	317,815	14,070,437
Selling and distribution expenses	(5,801,555)	(2,068,544)	(407,832)	(223,479)	(8,501,410)	(4,893,460)	(1,603,344)	(336,523)	(287,034)	(7,120,361)
Administrative expenses	(822,188)	(122,330)	(27,964)	-	(972,482)	(710,841)	(118,695)	(27,849)	-	(857,385)
Segment result	6,310,914	3,105,193	178,397	272,441	9,866,945	3,979,921	1,821,657	260,332	30,781	6,092,691

19.2 Segment wise operating results for the third quarter (Un-audited):

	September 30, 2025					September 30, 2024				
	Pharmaceutical	Nutritional	Diagnostic	Others	Total	Pharmaceutical	Nutritional	Diagnostic	Others	Total
Rupees in '000										
Sales	15,084,755	5,265,050	1,698,013	465,311	22,513,129	13,004,865	4,536,791	1,549,990	541,822	19,633,468
Less:										
Sales return	30,047	20,796	139,607	1,767	192,217	29,035	17,646	-	840	47,521
Trade discounts	998,951	283,794	-	15,151	1,297,896	880,096	250,627	-	13,526	1,144,249
Sales tax and excise duty	132,913	828,874	201,011	41,084	1,203,882	114,505	711,362	216,630	34,655	1,077,152
Sales - net	13,922,844	4,131,586	1,357,395	407,309	19,819,134	11,981,229	3,557,156	1,333,360	492,801	17,364,546
Cost of sales	(9,528,439)	(2,186,326)	(1,122,371)	(256,061)	(13,093,197)	(8,010,145)	(2,123,035)	(1,136,704)	(364,278)	(11,634,162)
Gross profit	4,394,405	1,945,260	235,024	151,248	6,725,937	3,971,084	1,434,121	196,656	128,523	5,730,384
Selling and distribution expenses	(2,181,372)	(634,469)	(106,101)	(52,201)	(2,974,143)	(1,753,490)	(438,303)	(118,547)	(94,511)	(2,404,851)
Administrative expenses	(286,442)	(42,615)	(5,230)	-	(334,287)	(251,065)	(40,290)	(9,127)	-	(300,482)
Segment result	1,926,591	1,268,176	123,693	99,047	3,417,507	1,966,529	955,528	68,982	34,012	3,025,051

19.3 Reconciliation of segment results with profit before taxation (Un-audited)

	Nine Months Ended		Quarter Ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
	----- Rupees in '000 -----			
Total segment results	9,866,945	6,092,691	3,417,507	3,025,051
Other income	603,335	541,111	186,590	83,003
Other charges	(1,256,699)	(578,954)	(430,365)	(250,259)
Finance costs	(55,363)	(18,587)	(17,659)	(5,988)
Profit before taxation	9,158,218	6,036,261	3,156,073	2,851,807

19.4 Geographical information (Un-audited)

	Nine Months Ended		Quarter Ended	
	September 30, 2025	September 30, 2024	September 30, 2025	September 30, 2024
	----- Rupees in '000 -----			
Sales to external customers, net of returns, discounts, sales tax and excise duty				
Pakistan	53,909,372	47,273,134	18,995,527	16,784,001
Afghanistan	1,455,511	1,277,592	602,384	278,644
Srilanka	35,095	25,483	14,392	10,477
Bangladesh	60,035	60,125	30,323	20,775
Switzerland	766,910	927,745	176,508	270,649
	56,226,923	49,564,079	19,819,134	17,364,546

19.5 Segment Assets and Liabilities

	UN-AUDITED					AUDITED				
	September 30, 2025					December 31, 2024				
	Pharmaceutical	Nutritional	Diagnostics	Others	Total	Pharmaceutical	Nutritional	Diagnostics	Others	Total
	----- (Rupees '000) -----									
Segment assets employed	25,253,182	1,894,487	6,516,719	402,898	34,067,286	21,969,642	1,427,383	6,087,714	282,458	29,767,197
Unallocated corporate assets					10,469,217					7,883,961
Total reported assets					44,536,503					37,651,158
Segment liabilities	10,212,746	1,297,583	1,208,552	84,950	12,803,831	8,737,863	914,550	1,001,686	59,508	10,713,607
Unallocated corporate liabilities					3,377,845					3,212,915
Total liabilities					16,181,676					13,926,522

20. DATE OF AUTHORISATION

These condensed interim financial statements were authorised for issue on October 29, 2025 by the Board of Directors of the Company.

Chief Executive Officer

Director

Chief Financial Officer



Abbott

life. to the fullest.®

